NCT07164794Not yet recruitingPhase 2
Memantine Hydrochloride in Prostate Cancer Patients
A Prospective Study of Memantine Hydrochloride for the Treatment of Prostate Cancer Patients
Source: ClinicalTrials.gov · Last updated 19 Nov 2025
Brief summary (registry, in English)
The goal of this clinical trial is to learn if long-term use of memantine hydrochloride can treat, prevent, or correct castration resistance and drug resistance in advanced prostate cancer. The study will enroll male patients aged 18 and older diagnosed with metastatic castration-resistant prostate cancer (mCRPC) who have previously failed first or second-line treatments. The main questions it aims to answer are: What is the progression-free survival (PFS) in patients treated with memantine hydrochloride? What is the disease control rate (DCR) and what is the change in Prostate-Specific Antigen (PSA) levels after treatment? Researchers will compare outcomes from participants in this single-arm study to an external historical control group of patients who received traditional treatment to see if the addition of memantine hydrochloride improves prognosis. Participants will be asked to do the following: Continue their standard of care treatment, which includes Androgen Deprivation Therapy (ADT) and a novel endocrine therapy. Take the study drug, memantine hydrochloride, with the dose gradually increasing over the first three weeks to a maintenance dose. Attend regular follow-up appointments for blood tests to check PSA levels and undergo imaging scans to monitor the disease status. These follow-ups will occur one month after starting the drug and every three months thereafter.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- First submitted
- 13 Aug 2025
- Start date
- Nov 2025
- Primary completion date
- Jun 2028
- Lead sponsor
- Bin Xu
- Diseases
- Prostate cancer
- NCT number
- NCT07164794
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 15
- From Nov 2025 to the primary completion date, Jun 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with a concurrent primary malignancy at another site.
Other illness
- Patients with metastatic prostate cancer at initial diagnosis who have not progressed to mCRPC.
Who the study is looking for
- Age ≥ 18 years
- Patients with metastatic castration-resistant prostate cancer (mCRPC) who have failed one or two prior lines of therapy. Patients with concomitant Alzheimer's disease will be prioritized for enrollment.
- Complete clinical baseline data must be available, and the patient must be willing to undergo long-term follow-up.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.